Preclinical studies have shown ALKS 37 targets the gastrointestinal system following oral administration, with limited systemic exposure. ALKS 37 is an element of ALKS 36, a combination drug candidate for the treating pain without the medial side effects of constipation. Related StoriesDrug that relieves opioid-induced constipation can help some cancer sufferers live longerNew computer-based modeling may help improve outcomes for babies with neonatal abstinence syndromeEgalet announces launch of OXAYDO Tablets and IMPACT-Rx initiativeAccording to IMS Health, over 200 million prescriptions were created for opioids in 2007 in the usa.In the Randomized Evaluation of Long-Term Anticoagulation Therapy , which compared warfarin and dabigatran in individuals with atrial fibrillation, there was an increased risk of acute coronary syndromes with dabigatran,19 although after further analysis of the info this difference was no longer significant.20,21 However, a recently available meta-analysis of seven noninferiority trials demonstrated a significantly higher risk of myocardial infarction or acute coronary syndromes with dabigatran than with the comparator.22 Whether dabigatran increases the threat of myocardial infarction is still unclear therefore.